DCN and Menkes disease: We also show as a proof-of-principle experiment that we can target a potential therapeutic molecule, DCN, to these same lesions by the CAR peptide and that the targeted therapy is significantly better in suppressing the fibrosis formation than the non-targeted therapy in the treatment of MD.